Ken Griffin Zynerba Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.5 - $0.72 $51,182 - $73,702
-102,364 Reduced 85.42%
17,471 $9,000
Q3 2022

Nov 14, 2022
BUY
$0.87 - $1.36 $104,256 - $162,975
119,835 New
119,835 $87,000
Q1 2022

May 16, 2022
SELL
$1.83 - $3.02 $163,841 - $270,383
-89,531 Reduced 68.24%
41,665 $86,000
Q4 2021

Feb 14, 2022
BUY
$2.88 - $4.3 $153,656 - $229,417
53,353 Added 68.54%
131,196 $0
Q3 2021

Nov 15, 2021
SELL
$3.72 - $5.35 $20,977 - $30,168
-5,639 Reduced 6.75%
77,843 $330,000
Q2 2021

Aug 16, 2021
SELL
$3.83 - $5.98 $491,726 - $767,760
-128,388 Reduced 60.6%
83,482 $0
Q1 2021

May 17, 2021
BUY
$3.33 - $8.76 $598,247 - $1.57 Million
179,654 Added 557.65%
211,870 $985,000
Q4 2020

Feb 16, 2021
BUY
$3.27 - $4.64 $11,556 - $16,397
3,534 Added 12.32%
32,216 $106,000
Q3 2020

Nov 16, 2020
BUY
$3.23 - $4.3 $58,492 - $77,868
18,109 Added 171.28%
28,682 $95,000
Q2 2020

Aug 14, 2020
SELL
$3.31 - $6.54 $19,505 - $38,540
-5,893 Reduced 35.79%
10,573 $36,000
Q1 2020

May 15, 2020
BUY
$2.9 - $6.16 $18,545 - $39,393
6,395 Added 63.5%
16,466 $63,000
Q4 2019

Feb 14, 2020
SELL
$5.61 - $8.57 $79,701 - $121,753
-14,207 Reduced 58.52%
10,071 $61,000
Q3 2018

Nov 13, 2018
BUY
$5.59 - $10.45 $135,714 - $253,705
24,278 New
24,278 $0

Others Institutions Holding ZYNE

# of Institutions
4
Shares Held
774K
Call Options Held
0
Put Options Held
0
View Full List

About Zynerba Pharmaceuticals, Inc.

ZYNE Quotes by TradingView
  • Ticker ZYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,753,100
  • Description
  • Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...
More about ZYNE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email